These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 23128852)

  • 1. Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia.
    Gross G; Wicke K; Drescher KU
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Feb; 386(2):155-66. PubMed ID: 23128852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions.
    Gross G; Drescher K
    Handb Exp Pharmacol; 2012; (213):167-210. PubMed ID: 23027416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
    Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
    Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia.
    Horacek J; Bubenikova-Valesova V; Kopecek M; Palenicek T; Dockery C; Mohr P; Höschl C
    CNS Drugs; 2006; 20(5):389-409. PubMed ID: 16696579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blonanserin ameliorates social deficit through dopamine-D
    Takeuchi S; Hida H; Uchida M; Naruse R; Yoshimi A; Kitagaki S; Ozaki N; Noda Y
    Neurochem Int; 2019 Sep; 128():127-134. PubMed ID: 30998952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive impairment in schizophrenia: a review of developmental and genetic models, and pro-cognitive profile of the optimised D(3) > D(2) antagonist, S33138.
    Millan MJ; Brocco M
    Therapie; 2008; 63(3):187-229. PubMed ID: 18718210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO.
    Graff-Guerrero A; Mamo D; Shammi CM; Mizrahi R; Marcon H; Barsoum P; Rusjan P; Houle S; Wilson AA; Kapur S
    Arch Gen Psychiatry; 2009 Jun; 66(6):606-15. PubMed ID: 19487625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
    Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY
    Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cognition, schizophrenia and the effect of antipsychotics].
    Stip E
    Encephale; 2006; 32(3 Pt 1):341-50. PubMed ID: 16840928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bitropic D3 Dopamine Receptor Selective Compounds as Potential Antipsychotics.
    Luedtke RR; Rangel-Barajas C; Malik M; Reichert DE; Mach RH
    Curr Pharm Des; 2015; 21(26):3700-24. PubMed ID: 26205291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range.
    Baba S; Enomoto T; Horisawa T; Hashimoto T; Ono M
    J Pharmacol Sci; 2015 Mar; 127(3):326-31. PubMed ID: 25837930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs.
    Svensson TH
    Brain Res Brain Res Rev; 2000 Mar; 31(2-3):320-9. PubMed ID: 10719159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
    Leucht S
    Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia.
    Xiberas X; Martinot JL; Mallet L; Artiges E; Loc'H C; Mazière B; Paillère-Martinot ML
    Br J Psychiatry; 2001 Dec; 179():503-8. PubMed ID: 11731352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
    Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
    Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.
    Kapur S; Seeman P
    Am J Psychiatry; 2001 Mar; 158(3):360-9. PubMed ID: 11229973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blonanserin, an antipsychotic and dopamine D₂/D₃receptor antagonist, and ameliorated alcohol dependence.
    Takaki M; Ujike H
    Clin Neuropharmacol; 2013; 36(2):68-9. PubMed ID: 23503552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, randomized, placebo-controlled study of the dopamine D₃ receptor antagonist ABT-925 in patients with acute schizophrenia.
    Redden L; Rendenbach-Mueller B; Abi-Saab WM; Katz DA; Goenjian A; Robieson WZ; Wang Y; Goss SL; Greco N; Saltarelli MD
    J Clin Psychopharmacol; 2011 Apr; 31(2):221-5. PubMed ID: 21346607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frontal fasciculi and psychotic symptoms in antipsychotic-naive patients with schizophrenia before and after 6 weeks of selective dopamine D2/3 receptor blockade.
    Ebdrup BH; Raghava JM; Nielsen MØ; Rostrup E; Glenthøj B
    J Psychiatry Neurosci; 2016 Mar; 41(2):133-41. PubMed ID: 26599135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct and indirect interactions of the dopamine D₃ receptor with glutamate pathways: implications for the treatment of schizophrenia.
    Sokoloff P; Leriche L; Diaz J; Louvel J; Pumain R
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Feb; 386(2):107-24. PubMed ID: 23001156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.